Alivus Life Sciences Q3 Results
- BSE: 543322
- NSE: ALIVUS
- ISIN: INE03Q201024
- Sector: Biotechnology & Drugs
BSE
919.55
5.65 (0.62%)
5.65 (0.62%)Volume2.59 K
Updated: Mon 9 Mar, 2026 | 15:28:00
NSE
919.754.70 (0.51%)
4.70 (0.51%)Volume68.32 K
Updated: Mon 9 Mar, 2026 | 15:43:57
Technical Trends
Long TermConsiders price movement over the last 6 months
Not Available
Short TermConsiders price movement over the last 1-2 weeks
Not Available
- Bearish
- Moderately Bearish
- Neutral
- Moderately Bullish
- Bullish
Insight: Trends unavailable at the moment.
Q3 Results Highlights
- Total Income₹672.89 Cr.(4.84%)
- Operating Profit₹185.96 Cr.(6.17%)
- Profit After Tax₹150.26 Cr.(9.71%)
- Operating Margin27.64%(1.27%)
Note: Comparison is on YoY basis
Quarterly - Alivus Life Sciences Q3 Results
*All figures in crores except per share values
| Fiscal Period | Dec 25 | Sep 24 | QoQ Comp | Dec 23 | YoY Comp |
|---|---|---|---|---|---|
| Total Operating Expense | 486.93 | 387.61 | 13.97% | 413.43 | 4.34% |
| Depreciation/ Amortization | 19.66 | 15.09 | 6.63% | 13.18 | 29.68% |
| Operating Income | 185.96 | 119.27 | 15.69% | 159.38 | 6.17% |
| Net Income | 150.26 | 95.32 | 15.56% | 118.77 | 9.71% |
| Other Operating Expenses Total | 98.83 | 84.89 | 5.71% | 87.00 | -1.74% |
| Net Income Before Taxes | 198.39 | 127.46 | 13.93% | 160.68 | 7.15% |
| Total Revenue | 672.89 | 506.88 | 14.44% | 572.80 | 4.84% |
| Selling/ General/ Admin Expenses Total | 66.37 | 62.44 | -0.05% | 71.05 | 1.03% |
| Diluted Normalized EPS | 13.80 | 7.75 | 30.44% | 9.67 | 23.88% |